All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Foralumab
Therapeutic Area: Gastroenterology Product Name: TZLS-401
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Recipient: Parexel Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 11, 2020
Details:
This clinical study will evaluate the safety, tolerability, and clinical activity of escalating doses of orally administered capsules of Foralumab. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Foralumab,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Trial arranged in collaboration with Harvard Medical School and Dr. Howard Weiner. A patent application was filed in July 2020 to protect the potential use of nasally administered Foralumab to treat COVID-19 either alone or in combination with other anti-viral drugs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TZLS-501
Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
United States Patent and Trademark Office has granted a patent for methods and use of fully human monoclonal antibody that recognizes both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Foralumab
Therapeutic Area: Gastroenterology Product Name: TZLS-401
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $57.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 05, 2020
Details:
Tiziana intends to use the net proceeds to advance the clinical development of Foralumab, to initiate a trial in HCC patients with Milciclib, to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general corporate purposes
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Foralumab,CAR-T Therapy
Therapeutic Area: Oncology Product Name: TZLS-401
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
Tiziana has submitted a patent application on potential use of Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), to improve success of CAR-T therapy for cancer and other human diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TZLS-501
Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: STC Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2020
Details:
Tiziana's proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dactinomycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Recipient: Rasna Therapeutics
Deal Size: $0.6 million Upfront Cash: $0.1 million
Deal Type: Acquisition April 24, 2020
Details:
Actinomycin-D from Rasna Therapeutics will expand Tiziana Life Sciences's pipeline. The drug is on the WHO's List of Essential Medicines as the most effective medicines needed in a health system.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TZLS-501
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
Details:
Development of this technology is a step forward toward expediting development of TZLS-501, for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TZLS-501
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: ThinkEquity
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 12, 2020
Details:
Net proceeds to be used to advance the clinical development of Foralumab for Crohn’s Disease and M.S (ii) to expedite clinical development of TZLS-501 for coronavirus COVID-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TZLS-501
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2020
Details:
Tiziana plans to administer TZLS-501 using a proprietary formulation technology. Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
